PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY

• K. Lorenz,
• T. Strüßmann,
• M. Trepel,
• G. Illerhaus,
• H. Pelz,
• C. Scholz,
• J. Duyster,
• R. Marks

Affiliations

K. Lorenz

1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg

T. Strüßmann

1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg

M. Trepel

2 Department of Hematology and Oncology, Universitätsklinikum Augsburg, Augsburg

G. Illerhaus

3 Department of Hematology, Oncology, and Palliative Medicine, Klinikum Stuttgart, Stuttgart

H. Pelz

4 Onkologie Offenburg, Offenburg

C. Scholz

5 Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany

J. Duyster

1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg

R. Marks

1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg